How has disruption to Chinese businesses and deals shifted as the virus itself has moved from China to the U.S.? Scott Yu and Meg Utterback discuss the pandemic's impact on international M&A, litigation, antitrust enforcement, and U.S. regulatory action against Chinese companies
Bo Yan and Taoye Ye of Haiwen & Partners discuss CBIRC's amended rules governing the regulatory approvals of non-bank financial institutions, which lower the bar for foreign investment in national asset management companies
U.S. agencies recommend stripping China Telecom of operating license over national security concerns; China knocks U.S. off top spot in global patent filing league table; and Chinese customs to increase checks on medical equipment exports amid complaints about low quality
CSRC defines strategic investors in private offering of shares, quoting of defaulted bond trading is subject to regulation and CBIRC clarifies the scope of medical insurance products with revisable premium rates.
JPMorgan set for full control of asset management business with minority partner buyout; Luckin Coffee reveals financial fraud amid growing concern over Chinese listings; and the U.S. set to ramp up tech export restrictions for China, report says.
Conditions are made clear for commercialization of collective land, China takes steps to promote international oil and gas trade, shareholder equity requirements for non-bank financial institutions are tightened.